

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
05 May 2022 (05.05.2022)



(10) International Publication Number  
**WO 2022/093121 A1**

(51) International Patent Classification:  
*C07K 16/18* (2006.01) *A61P 35/00* (2006.01)  
*A61K 39/395* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/SG2021/050653

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:  
26 October 2021 (26.10.2021)

**Published:**

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))  
— in black and white; the international application as filed  
contained color or greyscale and is available for download  
from PATENTSCOPE

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10202010654X 27 October 2020 (27.10.2020) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way,  
#20-10, Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **FONG, Wey Jia**; c/o Bioprocessing Technology  
Institute, 20, Biopolis Way, Centros, #04-01, Singapore  
138668 (SG). **CHOO, Boon Hwa**; c/o Bioprocessing Technology  
Institute, 20, Biopolis Way, Centros, #04-01, Singapore  
138668 (SG). **DING, Mei Yee Vanessa**; c/o Bioprocessing  
Technology Institute, 20, Biopolis Way, Centros, #04-01,  
Singapore 138668 (SG). **CHIN, Chui Ping**; c/o Bioprocessing  
Technology Institute, 20, Biopolis Way, Centros, #04-01,  
Singapore 138668 (SG).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**;  
10 Collyer Quay #07-01, Ocean Financial Centre, Singapore  
049315 (SG).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIGEN BINDING MOLECULES AND USES THEREOF

(57) Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.

